This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fass, L. Articles by Fefer, A. Search for Related Content PubMed PubMed Citation Articles by Fass, L. Articles by Fefer, A.

Studies of Adoptive Chemoimmunotherapy of a Friend Virus-induced Lymphoma¹

Division of Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195

Adult C57BL/6 mice inoculated with syngeneic Friend virus-induced lymphoma cells (FBL-3) on Day 0 were treated on Day 5 with sublethal cyclophosphamide (CY), 180 mg/kg, and C57BL/6 spleen cells. Untreated mice died on Day 15 (median). Spleen cells alone had no effect. When treated with CY alone, CY plus normal spleen cells, or CY plus spleen cells immunized to unrelated antigens, mice had prolonged survival to 26 days (median), and 1 of 60 mice survived >100 days. In contrast, treatment with CY plus spleen cells from donors preimmunized against FBL-3 cells was markedly effective, with 79 of 88 mice surviving tumor free >100 days. Freeze-thawing of the immune cells abolished their efficacy. The results showed that a disseminated antigenic lymphoma can be eradicated by noncurative, nonlethal chemotherapy and syngeneic spleen cells, but only if the latter were viable and immune to tumor-associated antigens.

¹ This work was supported by Grants CA 10777, CA 10895, and CA 05231 from the National Cancer Institute, NIH, USPHS, and by Institutional Grant IN-26 from the American Cancer Society.

² Special Fellow of the Leukemia Society of America.

³ Scholar of the Leukemia Society of America.

Received 12/13/71. Accepted 2/ 8/72.

This article has been cited by other articles:

				R. H. Rudolph, A. Fefer, E. D. Thomas, C. D. Buckner, R. A. Clift, and R. Storb Isogeneic Marrow Grafts for Hematologic Malignancy in Man Arch Intern Med, August 1, 1973; 132(2): 279 - 285. [Abstract] [PDF]